PMID: 11912814Mar 27, 2002Paper

Treatment strategies and new therapeutic advances for type 2 diabetes

The Diabetes Educator
J Rosenstock

Abstract

Because type 2 diabetes is caused by two defects, impaired insulin secretion and insulin resistance, logical management of diabetes will include combination therapies to treat this dual condition. Initial combination therapy should include an insulin secretagogue and an insulin sensitizer, with the addition of insulin in the evening if the HbA1c remains greater than 8%. Treatment to target should be clearly defined to achieve HbA1c < 7% unless there are specific individual considerations that make higher HbA1c levels acceptable or desirable. Patients are now treated earlier, when fasting blood glucose levels are in the 126 to 140 mg/dL range; and drugs with less chances of hypoglycemia are preferred at this stage. However, low-dose combination therapy as an early initial treatment, if HbA1c remains > 7%, is an emerging aggressive strategy that requires further consideration and further studies to prove its long-term efficacy and safety.

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Robert Moses
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Nancy J V Bohannon
© 2022 Meta ULC. All rights reserved